Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie's Disease
- PMID: 31445974
- PMCID: PMC6963116
- DOI: 10.1016/j.esxm.2019.07.003
Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie's Disease
Abstract
Introduction: Currently, there are several treatment options for Peyronie disease (PD). Although surgical interventions have better reported outcomes than conservative therapy, surgery is not suitable for all patients with PD. Therefore, oral therapy for PD is still a frequently used treatment due to low cost, convenience and limited side effects. However, current literature on the efficacy of oral therapy in PD is inconclusive. Pentoxifylline and colchicine have both shown some promise though further studies are required to confirm their effectiveness.
Aim: The aim of this study was to assess the efficacy of oral therapy for PD, including pentoxifylline and colchicine, coupled with the Andropenis penile traction therapy (PTT) extender on degree of penile curvature and plaque size.
Methods: Between March 2015 and June 2018, a prospectively collected database for patients receiving oral therapy for PD (pentoxifylline and/or colchicine) was reviewed.
Main outcome measure: Collected data variables were compared at baseline and after 6 months of treatment, including degree of curvature, plaque size, and penile Doppler ultrasound parameters (peak systolic velocity, minimum diastolic velocity, and pulsatility index). PTT was applied by the patient for a total of 1 hour per day for 6 months.
Results: A total of 46 patients were involved in this study. Mean age was 56 ± 10 years. There was a significant decrease in the degree of penile curvature after 6 months (55.8º ± 20º vs 41.4º ± 20.8º; P = .03). Likewise, the plaque size decreased significantly from 5.42 ± 2.7 to 2.42 ± 1.71 cm2; P = .0001. There was a significant increase in the peak systolic velocity from 29.8 ± 10.02 to 38.2 ± 11cm/sec; P = .02, whereas no statistically significant difference could be detected regarding end diastolic velocity (M = 0.56 ± 3.1 vs 1.59; P = .415) or pulsatility index (Mdiff = 0.03; CI = -0.06 to 0.12; P = .473). Furthermore, there was no statistically significant difference in medication type of pentoxifylline or colchicine (Mdiff = 17.23; CI = -3.31 to 37.77; P = .09).
Conclusion: Altogether, pentoxifylline and colchicine, taken with concomitant PTT, present a potentially convenient, low cost, and effective treatment for penile curvature and plaque resulting from PD. Prospective randomized trials are still required for better evaluation of the course of PD with patients undergoing conservative management. Ibrahim A, Gazzard L, Alharbi M, et al. Evaluation of Oral Pentoxifylline, Colchicine, and Penile Traction for the Management of Peyronie's Disease. Sex Med 2019;7:459-463.
Keywords: Colchicine; Erectile Dysfunction; Penile Traction; Pentoxifylline; Peyronie’s Disease.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Outcomes of RestoreX Penile Traction Therapy in Men With Peyronie's Disease: Results From Open Label and Follow-up Phases.J Sex Med. 2020 Dec;17(12):2462-2471. doi: 10.1016/j.jsxm.2020.10.003. Epub 2020 Nov 20. J Sex Med. 2020. PMID: 33223425 Clinical Trial.
-
Efficacy of Combined Collagenase Clostridium histolyticum and RestoreX Penile Traction Therapy in Men with Peyronie's Disease.J Sex Med. 2019 Jun;16(6):891-900. doi: 10.1016/j.jsxm.2019.03.007. Epub 2019 Apr 5. J Sex Med. 2019. PMID: 30956106
-
Penile Traction Therapy and Vacuum Erection Devices in Peyronie's Disease.Sex Med Rev. 2019 Apr;7(2):338-348. doi: 10.1016/j.sxmr.2018.02.005. Epub 2018 Apr 7. Sex Med Rev. 2019. PMID: 29631979 Review.
-
A double-blind placebo-controlled study of the efficacy and safety of pentoxifylline in early chronic Peyronie's disease.BJU Int. 2010 Jul;106(2):240-8. doi: 10.1111/j.1464-410X.2009.09041.x. Epub 2009 Oct 26. BJU Int. 2010. Retraction in: BJU Int. 2015 Mar;115(3):E10. doi: 10.1111/bju.13063. PMID: 19863517 Retracted. Clinical Trial.
-
Review of Management Options for Patients With Atypical Peyronie's Disease.Sex Med Rev. 2017 Apr;5(2):211-221. doi: 10.1016/j.sxmr.2016.07.004. Epub 2016 Aug 17. Sex Med Rev. 2017. PMID: 27544298 Review.
Cited by
-
Recent advances in managing Peyronie's disease.F1000Res. 2020 May 20;9:F1000 Faculty Rev-381. doi: 10.12688/f1000research.20557.1. eCollection 2020. F1000Res. 2020. PMID: 32518629 Free PMC article. Review.
-
Peyronie's disease - outcomes of collagenase clostridium histolyticum injection: A systematic review.Arab J Urol. 2021 Aug 16;19(3):363-369. doi: 10.1080/2090598X.2021.1957411. eCollection 2021. Arab J Urol. 2021. PMID: 34552787 Free PMC article. Review.
-
Impact of Race and Ethnicity on Clinical Outcomes of Collagenase Clostridium histolyticum in Patients With Peyronie's Disease Across Kaiser Permanente Southern California Database.Perm J. 2025 Mar 14;29(1):61-68. doi: 10.7812/TPP/24.111. Epub 2024 Dec 12. Perm J. 2025. PMID: 39663827 Free PMC article.
-
Oxidative Mechanism of Peyronie's Disease and Effectiveness of Pentoxifylline in the Therapeutic Management: A Narrative Review.Antioxidants (Basel). 2025 Feb 12;14(2):208. doi: 10.3390/antiox14020208. Antioxidants (Basel). 2025. PMID: 40002394 Free PMC article. Review.
-
Protective effects of pentoxifylline against chlorine-induced acute lung injury in rats.BMC Pharmacol Toxicol. 2023 Feb 27;24(1):12. doi: 10.1186/s40360-023-00645-2. BMC Pharmacol Toxicol. 2023. PMID: 36850013 Free PMC article.
References
-
- Hellstrom W.J. Medical management of Peyronie's disease. J Androl. 2009;30:397–405. - PubMed
-
- Sommer F., Schwarzer U., Wassmer G. Epidemiology of Peyronie's disease. Int J Impot Res. 2002;14:379–383. - PubMed
-
- La Pera G., Pescatori E.S., Calabrese M. Peyronie’s disease: Prevalence and association with cigarette smoking. A multicenter population-based study in men aged 50-69 years. Eur Urol. 2001;40:525–530. - PubMed
-
- Abern M.R., Larsen S., Levine L.A. Combination of penile traction, intralesional verapamil, and oral therapies for Peyronie's disease. J Sex Med. 2012;9:288–295. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources